83 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00327 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 2.3 ± 0.2 μM |
| dbacp00328 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 2.3 ± 0.2 μM |
| dbacp00329 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 2.3 ± 0.2 μM |
| dbacp00330 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 2.3 ± 0.2 μM |
| dbacp00331 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 2.3 ± 0.2 μM |
| dbacp00367 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 4.6 ± 0.2 μM |
| dbacp00368 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 4.6 ± 0.2 μM |
| dbacp00369 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 4.6 ± 0.2 μM |
| dbacp00370 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 4.6 ± 0.2 μM |
| dbacp00371 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 4.6 ± 0.2 μM |
| dbacp00408 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 3.0 ± 0.1 μM |
| dbacp00409 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 3.0 ± 0.1 μM |
| dbacp00410 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 3.0 ± 0.1 μM |
| dbacp00411 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 3.0 ± 0.1 μM |
| dbacp00412 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 3.0 ± 0.1 μM |
| dbacp00445 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 1.7 ± 0.1 μM |
| dbacp00446 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 1.7 ± 0.1 μM |
| dbacp00447 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 1.7 ± 0.1 μM |
| dbacp00448 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 1.7 ± 0.1 μM |
| dbacp00449 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 1.7 ± 0.1 μM |
| dbacp00485 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00486 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 2.0 ± 0.1 μM |
| dbacp00487 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00488 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00489 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00525 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 5.0 ± 0.3 μM |
| dbacp00526 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 5.0 ± 0.3 μM |
| dbacp00527 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 5.0 ± 0.3 μM |
| dbacp00528 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 5.0 ± 0.3 μM |
| dbacp00529 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 5.0 ± 0.3 μM |
| dbacp00550 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00551 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 4.0 ± 0.1 μM |
| dbacp00552 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00553 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00554 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00578 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 10.3 ± 1.1 μM |
| dbacp00579 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 10.3 ± 1.1 μM |
| dbacp00580 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 10.3 ± 1.1 μM |
| dbacp00581 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 10.3 ± 1.1 μM |
| dbacp00582 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 10.3 ± 1.1 μM |
| dbacp00626 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00627 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 4.0 ± 0.1 μM |
| dbacp00628 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00629 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00630 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00651 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 5.4 ± 0.3 μM |
| dbacp00652 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 5.4 ± 0.3 μM |
| dbacp00653 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 5.4 ± 0.3 μM |
| dbacp00654 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 5.4 ± 0.3 μM |
| dbacp00655 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 5.4 ± 0.3 μM |
| dbacp00681 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00682 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 5.1 ± 0.3 μM |
| dbacp00683 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00684 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00685 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00989 | Agelaia-MPI | INWLKLGKAIIDAL | Artistic wasp | Antinociceptive activity; Membrane disruption | Not specified | MM96L | Melanoma | CC50 : <10 µM |
| dbacp02400 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 2.9 ± 0.1 μM |
| dbacp02401 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid leukemia | CC50 : 2.9 ± 0.1 μM |
| dbacp02402 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 2.9 ± 0.1 μM |
| dbacp02403 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 2.9 ± 0.1 μM |
| dbacp02404 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 2.9 ± 0.1 μM |
| dbacp03125 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Fluorescence-based assay using a Fluorescence Imaging Plate Reader | MM96L | Epithelial cancer | CC50 : 3.7 ± 0.2 μM |
| dbacp03139 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 3.7 ± 0.2 μM |
| dbacp03140 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid leukemia | CC50 : 3.7 ± 0.2 μM |
| dbacp03141 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 3.7 ± 0.2 μM |
| dbacp03142 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 3.7 ± 0.2 μM |
| dbacp03143 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 3.7 ± 0.2 μM |
| dbacp06804 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 2.3 ± 0.2 μM |
| dbacp06810 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 2.0 ± 0.1 μM |
| dbacp06816 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 3.0 ± 0.1 μM |
| dbacp06820 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 4.6 ± 0.2 μM |
| dbacp06826 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 1.7 ± 0.1 μM |
| dbacp06832 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 10.3 ± 1.1 μM |
| dbacp06838 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 5.4 ± 0.3 μM |
| dbacp07468 | Protonectin | ILGTILGLLKGL | Parachartergus fraternus | Cell penetration without toxic accumulation | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 14.8 ± 0.9 µM |
| dbacp07470 | Protonectin-F | IFGTILGFLKGL | Protonoectin | Cell penetration without toxic accumulation | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 16.0 ± 1.2 µM |
| dbacp07803 | cT1 | KWCFRVCYRGICYRRCRG | Synthetic | Not Available | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 1.3 ± 0.1 µM |
| dbacp07814 | [W2S]cT1 | KSCFRVCYRGICYRRCRG | Synthetic | Not Available | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 2.0 ± 0.1 µM |
| dbacp07820 | [Y8S-I11S]cT1 | KWCFRVCSRGSCYRRCRG | Synthetic | Not Available | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 17.3 ± 1.0 µM |
| dbacp07825 | [R14S]cT1 | KWCFRVCYRGICYSRCRG | Synthetic | Not Available | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 1.7 ± 0.1 µM |
| dbacp07830 | [R17S]cT1 | KWCFRVCYRGICYRRCSG | Synthetic | Not Available | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 1.8 ± 0.1 µM |
| dbacp07838 | [G18K]cT1 | KWCFRVCYRGICYRRCRK | Synthetic | Not Available | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 1.0 ± 0.1 µM |
| dbacp07843 | [I11F-G18K]cT1 | KWCFRVCYRGFCYRRCRK | Synthetic | Not Available | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 1.3 ± 0.1 µM |